USNA
USANA HEALTH SCIENCES INC
Next earnings Jul 20, 2026 (after close) · consensus $0.44 EPS, $240M rev
Last earnings +3.8% on 2026-05-05
$20.70
▲ +5.18%$20.70▼ -31.80%
over 1Y
L $16.90EODHDH $35.43
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+5.2%
1W+9.5%
1M+10.1%
3M+22.3%
YTD+6.5%
1Y-31.8%
Hold
Conviction
Horizon
Medium (3–12mo)
Street · 6 analysts
Sell
Revenue grew 8.3% YoY; but thin net margin (1.2%).
Revenue (FY2026) $925M · FY2026
The read
Middling fundamentals and a rich price (~80% above fair value) leave little margin of safety — a wait-and-see.
USANA HEALTH SCIENCES INC shows $925M in FY2026 revenue (+8.3% YoY), a 1.2% net margin, and 2.0% ROE.
Financials · annual, by fiscal year
| Line item | FY21 | FY22 | FY23 | FY24 | FY26 |
|---|---|---|---|---|---|
| Revenue | $1.13B | $999M | $921M | $855M | $925M |
| Gross profit | $926M | $805M | $744M | $693M | $724M |
| Operating income | $176M | $108M | $93.1M | $66.3M | $37.4M |
| Net income | $125M | $69.3M | $63.8M | $42.0M | $10.8M |
| Diluted EPS | $5.86 | $3.59 | $3.30 | $2.19 | $0.58 |
| Net margin | 11.0% | 6.9% | 6.9% | 4.9% | 1.2% |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$224M
EV / EBITDA3.2
EV / Sales0.2
EV / FCF26.2
P / FCF44.8
PEG (trailing)—
Earnings yield2.8%
FCF yield2.2%
Quality & risk
ROIC (est.)5.5%
Free cash flow$8.53M
Total debt—
Net cash$158M
Altman Z-Score4.01 safe
Piotroski F-Score6/8
Capital returns
Buyback yield7.2%
Dividend yield (est.)—
Shareholder yield7.2%
Shares Δ YoY-2.4%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsSome governance/structural items recently, but no outright red flags.
Recent filings
all on EDGAR ↗4Period ending 2026-06-162026-06-18open ↗144Filing2026-06-16open ↗4Period ending 2026-06-122026-06-16open ↗144Filing2026-06-15open ↗11-KPeriod ending 2025-12-312026-06-15open ↗4Period ending 2026-06-082026-06-08open ↗144Filing2026-06-08open ↗4Period ending 2026-06-012026-06-01open ↗4Period ending 2026-05-282026-05-29open ↗144Filing2026-05-28open ↗4Period ending 2026-05-272026-05-28open ↗144Filing2026-05-27open ↗
Frequently asked
- Is USANA HEALTH SCIENCES INC (USNA) a buy?
- USNA currently carries a Hold rating with 3/5 conviction, derived from its latest SEC filings. Revenue grew 8.3% YoY; but thin net margin (1.2%).
- What is USNA's fair value?
- A Modified-Graham model based on USNA's SEC fundamentals estimates a fair value of about $4.22. It is an estimate from reported earnings, not a price target.
- Is USNA overvalued or undervalued?
- Against a Modified-Graham fair-value estimate, USNA currently appears overvalued relative to its SEC-grounded earnings power.
- What is USANA HEALTH SCIENCES INC's quality score?
- USNA scores 61.509803921568626/100 (grade C+) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0000896264, latest 10-Q filed 2026-05-12) · EODHD · as of 6/26/2026, 8:11:35 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.